Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). (Q40848113)

24 September 2017

1 reference

title

Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). (English)

1 reference

24 September 2017

1 reference

W A Denny

1

1 reference

PubMed ID

8375017

24 September 2017

W R Wilson

series ordinal

2

1 reference

24 September 2017

1 June 1993

1 reference

Cancer and Metastasis Reviews

24 September 2017

1 reference

24 September 2017

12

1 reference

24 September 2017

135-151

1 reference

24 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00689806

24 September 2017

0 references

cites work

Reoxygenation and repopulation in irradiated tumors.

1 reference

12 December 2020

A marker for hypoxic cells in tumours with potential clinical applicability

1 reference

12 December 2020

Use of a high frequency ultrasound microscope to image the action of 2-nitroimidazoles in multicellular spheroids

1 reference

12 December 2020

The effects of single dose oral hydralazine on blood flow through human lung tumours.

1 reference

12 December 2020

Cell kinetics and chemotherapy: a critical review

1 reference

12 December 2020

Manipulation of oxygenation in a human tumour xenograft with BW12C or hydralazine: effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU-1069

1 reference

12 December 2020

Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha

1 reference

12 December 2020

Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells

1 reference

12 December 2020

Distribution of misonidazole adducts in 9L gliosarcoma tumors and spheroids: implications for oxygen distribution.

1 reference

12 December 2020

The properties of total adducts and interstrand crosslinks in the DNA of cells treated with CB 1954. Exceptional frequency and stability of the crosslink

1 reference

12 December 2020

Antibody-directed enzyme/prodrug therapy (ADEPT).

1 reference

12 December 2020

Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy

1 reference

12 December 2020

Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid

1 reference

12 December 2020

Acid pH in tumors and its potential for therapeutic exploitation

1 reference

12 December 2020

Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole

1 reference

12 December 2020

Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species

1 reference

12 December 2020

Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233

1 reference

12 December 2020

Radiation Survival of Cells from Spheroids Grown in Different Oxygen Concentrations

1 reference

12 December 2020

Radiosensitizing and Cytotoxicity Studies with CB 1954 (2,4-Dinitro-5-Aziridinylbenzamide)

1 reference

12 December 2020

A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells

1 reference

12 December 2020

The effect of hypoxia and low pH on the cytotoxicity of chlorambucil

1 reference

12 December 2020

Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid

1 reference

12 December 2020

Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study

1 reference

12 December 2020

Activation of radiosensitizers by hypoxic cells

1 reference

12 December 2020

Cytotoxic Effects of the Hypoxic Cell Radiosensitizer Ro 7-0582 to Tumor Cells in Vivo

1 reference

12 December 2020

Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo

1 reference

12 December 2020

Definitive evidence for hypoxic cells influencing cure in cancer therapy

1 reference

12 December 2020

Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.

1 reference

12 December 2020

Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).

1 reference

12 December 2020

Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma

1 reference

12 December 2020

Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown

1 reference

12 December 2020

The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain

1 reference

12 December 2020

Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study

1 reference

12 December 2020

The nitroreductase enzyme in walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-YL)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)

1 reference

12 December 2020

Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU-1069

1 reference

12 December 2020

The radiation sensitivities of R3327-H and R3327-AT rat prostate adenocarcinomas

1 reference

12 December 2020

Molecular orbital calculations on tumour-inhibitory phenyl aziridines: QSARs

1 reference

12 December 2020

Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs

1 reference

12 December 2020

Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours

1 reference

12 December 2020

Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions

1 reference

12 December 2020

Dosimetric aspects of radiolabeled antibodies for tumor therapy

1 reference

12 December 2020

Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells

1 reference

12 December 2020

Sensitizing and toxicity properties of misonidazole and its derivatives

1 reference

12 December 2020

Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection

1 reference

12 December 2020

Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice

1 reference

12 December 2020

Role of glutathione in the hypoxic cell cytotoxicity of misonidazole.

1 reference

12 December 2020

Pharmacological modification of tumor blood flow: lack of correlation between alteration of mean arterial blood pressure and changes in tumor perfusion

1 reference

12 December 2020

Induction of hypoxia in normal and malignant tissues by changing the oxygen affinity of hemoglobin--implications for therapy

1 reference

12 December 2020

Targeting Bioreductive Drugs to Tumours: Is It Necessary to Manipulate Blood Flow

1 reference

12 December 2020

Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells

1 reference

12 December 2020

Cytotoxicity, radiosensitization, antitumor activity, and interaction with hyperthermia of a Co(III) mustard complex.

1 reference

12 December 2020

Structure-activity relationships in antitumor aniline mustards

1 reference

12 December 2020

Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors

1 reference

12 December 2020

A novel technique for measuring human tissue pO2 at the cellular level

1 reference

12 December 2020

Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs

1 reference

12 December 2020

Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma

1 reference

12 December 2020

Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide

1 reference

12 December 2020

Influence of pH on the cytotoxic activity of chlorambucil.

1 reference

12 December 2020

Radiotherapy and hyperbaric oxygen in head and neck cancer. Interim report of second clinical trial

1 reference

12 December 2020

Hydralazine does not increase hypoxia in tumors growing in preirradiated tissue

1 reference

12 December 2020

Binding of misonidazole to V79 spheroids and fragments of Dunning rat prostatic and human colon carcinomas in vitro: diffusion of oxygen and reactive metabolites

1 reference

12 December 2020

Intermittent blood flow in a murine tumor: radiobiological effects

1 reference

12 December 2020

Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9

1 reference

12 December 2020

Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines

1 reference

12 December 2020

Therapeutic advantage of hypoxic cells in tumors: a theoretical study

1 reference

12 December 2020

Drug induced perturbations in tumor blood flow: therapeutic potential and possible limitations

1 reference

12 December 2020

Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00689806

1 reference

PubMed ID

8375017

Dimensions Publication ID

24 September 2017

0 references

1 reference

PubMed ID

8375017